Centiva Capital LP Grows Position in Novo Nordisk A/S (NYSE:NVO)

Centiva Capital LP increased its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 138.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,898 shares of the company's stock after buying an additional 12,132 shares during the period. Centiva Capital LP's holdings in Novo Nordisk A/S were worth $2,488,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NVO. International Assets Investment Management LLC grew its holdings in shares of Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company's stock valued at $215,942,000 after buying an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC increased its holdings in Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company's stock worth $227,516,000 after purchasing an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd purchased a new stake in shares of Novo Nordisk A/S in the third quarter worth approximately $98,765,000. Marshall Wace LLP lifted its holdings in shares of Novo Nordisk A/S by 34,472.1% in the second quarter. Marshall Wace LLP now owns 691,441 shares of the company's stock valued at $98,696,000 after purchasing an additional 689,441 shares in the last quarter. Finally, Sanctuary Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the second quarter valued at approximately $41,646,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock traded up $0.62 during trading hours on Tuesday, reaching $109.29. The company had a trading volume of 3,433,125 shares, compared to its average volume of 4,505,694. The firm has a market cap of $490.44 billion, a PE ratio of 35.18, a price-to-earnings-growth ratio of 1.38 and a beta of 0.40. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The business has a fifty day simple moving average of $112.81 and a 200 day simple moving average of $127.92.

Analysts Set New Price Targets

Several brokerages have weighed in on NVO. Cantor Fitzgerald restated an "overweight" rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating on the stock in a research report on Thursday, October 17th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.